Vaccine

Abstract

The present invention relates to the field of bacterial polysaccharide antigen vaccines. In particular the present invention relates to specific advantageous pneumococcal polysaccharide conjugates adjuvanted with 3D-MPL and substantially devoid of aluminium-based adjuvant.

1 - 19 . (canceled)  
     
     
         20 . A lyophilised antigenic composition comprising a conjugated  Streptococcus pneumoniae  capsular polysaccharide serotype 6B which is adjuvanted with 3-0 deacylated monophosphoryl lipid A (3D-MPL) and substantially devoid of aluminium-based adjuvant.  
     
     
         21 . The lyophilised antigenic composition of  claim 20  further comprising one or more pneumococcal polysaccharide conjugates chosen from the group consisting of: 
 serotype 4;    serotype 18C;    serotype 19F; and    serotype 23F.    
     
     
         22 . The lyophilised antigenic composition of  claim 20  or  21  wherein the  Streptococcus pneumoniae  capsular polysaccharides are conjugated to a protein chosen from the group consisting of: 
 tetanus toxoid;    OMPC of  Neisseria meningitidis;      diphtheria toxoid;    pneumolysin of  Streptococcus pneumoniae;  and    CRM197.    
     
     
         23 . The antigenic composition of  claim 20  or  21  wherein the  Streptococcus pneumoniae  capsular polysaccharides are conjugated to protein D of  Haemophilus influenzae.    
     
     
         24 . The lyophilised antigenic composition of claims  20  or  21  containing conjugates of  Streptococcus pneumoniae  capsular polysaccharide serotypes 6B, 14, 19F and 23F.  
     
     
         25 . The lyophilised antigenic composition of claims  20 ,  21  or  22  containing conjugates of  Streptococcus pneumoniae  capsular polysaccharide serotypes 4, 6B, 9V, 14, 18C, 19F and 23F.  
     
     
         26 . The lyophilised antigenic composition of claims  20 ,  21  or  22  containing conjugates of  Streptococcus pneumoniae  capsular polysaccharide serotypes 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.  
     
     
         27 . The lyophilised antigenic composition of claims  20 ,  21  or  22  containing conjugates of  Streptococcus pneumoniae  capsular polysaccharide serotypes 1, 3, 4, 5, 6B, 7F, 8, 9V, 12F, 14, 18C, 19F and 23F.  
     
     
         28 . The lyophilised antigenic composition of claims  20 ,  21  or  22  containing conjugates of  Streptococcus pneumoniae  capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.  
     
     
         29 . The lyophilised antigenic composition of claims  20 ,  21  or  22  containing conjugates of  Streptococcus pneumoniae  capsular polysaccharide serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F.  
     
     
         30 . The lyophilised antigenic composition of claims  20 ,  21  or  22 , which is a vaccine composition.  
     
     
         31 . An antigenic composition comprising the lyophilised antigenic composition of claims  20 ,  21  or  22  reconstituted with a diluent.  
     
     
         32 . A method of making an antigenic composition comprising the step of reconstituting the lyophilised antigenic composition of claims  20 ,  21  or  22  with a diluent.  
     
     
         33 . A method of inducing an immune response to a  Streptococcus pneumoniae  capsular polysaccharide conjugate, said method comprising administering a safe and effective amount of the antigenic composition of  claim 31  to a patient.